News
Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback